Home/Pipeline/Target-04

Target-04

ALS

DiscoveryActive

Key Facts

Indication

ALS

Phase

Discovery

Status

Active

Company

Verge Genomics

About Verge Genomics

Verge Genomics is a private, clinical-stage biotech leveraging a proprietary AI platform, CONVERGE®, to discover and develop novel therapeutics. The company's lead program, VRG50635, a PIKfyve inhibitor for ALS, is in Phase 1, marking a key milestone of discovering a novel target and developing a clinical candidate entirely in-house. With a pipeline spanning neuroscience, metabolic, and immunology indications, Verge aims to address diseases with complex biology and high unmet need. The company is led by a team combining drug development expertise with technology leadership.

View full company profile

Therapeutic Areas

Neuroscience Metabolic Immunology Rare Diseases

Other ALS Drugs

Drug	Company	Phase	Status
Stem Cell Program	BioArctic	Research	Active
Eolo40 NCE	Eolo Pharma	Discovery	Active
New targets program	Treeway	Preclinical	Active
SYF2 Program	AcuraStem	Discovery	Active
Target-03	Verge Genomics	Discovery	Active
BIIB105 (ATXN2 ASO)	Biogen	Phase 2	Active
Undisclosed Program	bioarctic-ab	Discovery	Research